GlassScriptPhysician profile
Daniel Ellis Marcadis
NPI 1164484663
$4,000.85
in general payments reported to CMS, 2019-2025
28 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $168 · 2021: $331 · 2022: $782 · 2023: $587 · 2024: $888 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.16 | 2019-2025 | |
| Janssen Biotech, INC. | $427.65 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.93 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $231.97 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $195.63 | 2019-2024 | Linzess |
| Genzyme Corporation | $180.53 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.78 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $134.10 | 2024-2025 | |
| Celgene Corporation | $127.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $94.04 | 2023-2025 | Voquezna |
| Cook Medical LLC | $87.16 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $70.40 | 2024 | |
| Boston Scientific Corporation | $69.64 | 2023-2025 | General - Metal Stents - G.I., Exalt Model D, Watchman Access System |
| Intercept Pharmaceuticals, INC. | $69.31 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $62.34 | 2022-2023 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $59.64 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $45.69 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $39.58 | 2021-2023 | |
| Madrigal Pharmaceuticals | $33.84 | 2025 | Rezdiffra |
| Dova Pharmaceuticals | $32.13 | 2019 | |
| Medtronic, INC. | $28.99 | 2021 | |
| Covidien LP | $28.78 | 2020 | |
| Daiichi Sankyo INC. | $25.36 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.35 | 2022 | |
| Lilly USA, LLC | $20.75 | 2024 | Omvoh |
| Fresenius Kabi USA, LLC | $17.56 | 2023 | Idacio |
| Intra-Sana Laboratories | $14.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marcadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.